1. View Report Details
Global Renal Denervation Market
-------------------------------------------------
2012

2. View Report Details
Executive Summary
Affecting the lives of millions of people across the globe, hypertension is a chronic medical condition which substantially
raises the risk of cardiac malfunction, kidney diseases and insulin resistance. However if the condition is tamed by
managing the blood pressure, it suppresses the risk of occurrence of adverse events significantly. But when not treated
timely, it increases the risk of mortality from ischemic heart disease and stroke two folds.
Renal artery denervation (RDN) is a novel therapeutic paradigm meant for treating the resistant hypertension. Basically,
RDN is a catheter-based therapy which employs either radiofrequency or ultrasound energy for tampering the renal
arteries sympathetic nerves whose hyperactivity causes treatment-resistant hypertension.
RDN devices and technologies are the most sought after innovations in the field of medical technology as they provide for
an approach for managing and controlling the resistant hypertension, something that wasn’t available in the paramedics’
field before.
Developing novel medical devices using technologies which employ high frequency radiations has been a widely accepted
trend these days. The companies operating in this field have been manufacturing devices which are used in the diagnosis
and treatment of numerous medical conditions like cancer and hypertension. Despite being a technology which principally
works using radiations for medical therapy, RDN has been proven minimally invasive and efficient when practiced
heedfully.
The ongoing trends in the respective market include Medtronic’s HTN-3 pivotal study, development of novel renal
denervation devices, devising of baroreceptor stimulation technology, ongoing clinical trials and techniques to address the
existing limitations of the current technologies. The drivers promoting RDN market’s growth incorporate factors like
increasing cases of hypertension, increasing expenditure on healthcare, rising adult population worldwide, and increasing
global GNI. Although it’s been a new development in the field of paramedics, it has its own share of difficulties and hurdles
where situations and elements such as limitations of invasive technology and treatment-resistant hypertension have been
posing acute challenges. The leading players dominating RDN market space include Medtronic Inc., Boston Scientific
Corp., St. Jude Medical Inc. and Covidien.
This RDN Market report attempts to elicit the rapidly evolving market by scrutinizing the novel technologies, product
offerings, top notch industry players and their respective market shares.

3. Global Renal Denervation Market : Overview
Global Interventional Hypertension Procedures (2011-2015E)
 The estimated size of the interventional hypertension
treatment market is expected to reach somewhere around
US$..........million by 2015 in the US and developed Europe
and is projected to be US$........billion by 2020.……………
 In 2011, the number of interventional hypertension
procedures was …… and are expected to rise by
………….% reaching ……….. in 2012.…………….
 In the US, hypertension cases have been rising at a
significant rate, which is evident by the fact that the
number of cases as a percentage of adult population
increased from …….% in 2010 to ………….% in
2011……………
 In 2010, the number of patients suffering with hypertension
as a percentage of total adult population in the Europe was
……..%, which increased to ……….% in 2011. However
the number of patients treated for hypertension as a
Hypertension Prevalence in the US (2010-2015E) percentage of total hypertension patients has also been on
a rise. ……………….
 The key competitors of the industry include Boston
Scientific, Covedien and St. Jude.……………..

4. Renal Denervation in Various Regions
Hypertension Prevalence in the Developed Europe
(2010-2015E)  Europe accounts for the largest share of the global renal denervation
market, in terms of procedure, with approximately …..% or ……. RDN
procedures as of 2011.
 The next major contributor is the US with …….RDN procedures, or
around ……..%, of the global market for RDN procedures. The
remaining ………….. procedures were performed in the rest of the
world during the year. ……………………..
 In terms of revenues, as of 2011 the staggering share worth
US$...........million (……%) was accounted by Europe, followed by the
US with US$....... million revenues, thereby constituting approximately
…………….% of the global RDN market revenues.………………….
Worldwide RDN Revenue Share by Region (2011)
Worldwide RDN Procedure Share by Region (2011)
)

5. Global RDN Market Growth
Global RDN Market Growth (2011-2015E) Worldwide RDN Revenue Share by Geography (2012E and 2020E)
 The global renal denervation market is projected to grow at a CAGR of ………% over a period of 4 years from US$..... million 2011
to US$........ million in 2015.
 In terms of revenue generation in the RDN market, the region expected to be claim the top spot for the year 2012 is Europe, with
an estimated revenue share worth ….%. However, this share is expected to come down to …….% by 2020 as it is likely to be
taken over by other geographies like Japan, the US, and other countries.
 Key Trends include: Medtronic’s HTN-3 pivotal study, development of novel renal denervation devices, devising of baroreceptor
stimulation technology , ongoing clinical trials and addressing the existing limitations of the current technologies.
 Growth Drivers include: increasing cases of hypertension, increasing expenditure on healthcare, rising adult population ,
worldwide and increasing global GNI (gross national income) .
 Challenges include: limitations of invasive technology for treatment and treatment-resistant hypertension ………………………….
Note: Market attractiveness is inverse of penetration. Low penetration means high attractiveness and vice-versa

6. View Report Details
Table of Contents
Tables and Charts
1. Hypertension
List of Charts
1.1 Overview
BP Pattern across various Stages of Hypertension
BP Pattern
Global Interventional Hypertension Procedures (2011-2015E)
Essential Hypertension
Hypertension Prevalence in the US (2010-2015E)
Treatment Options
Hypertension Prevalence in the Developed Europe (2010-2015E)
RDN Device Comparison – 30-Day BP Change
1.2 Global Hypertension Market
Worldwide RDN Procedure Share by Region (2011)
Worldwide RDN Revenue Share by Region (2011)
Market Overview
Rising Global Adult Population (2007-2012E)
Procedure Growth
World Gross National Income (2005-2010)
Market Share
Medtronic’s Revenue Share by Business Segments (2012)
Medtronic’s Revenue and Net Earnings Analysis (2009-2012)
1.3 The US Hypertension Market
St. Jude Medical’s Revenue Share by Business Segments (2011)
St. Jude Medical’s Revenue and Net Earnings Analysis (2007-2011)
Hypertension Prevalence
Boston Scientific’s Revenue Share by Business Segments (2011)
Market Opportunity
Boston Scientific’s Revenue and Net Income Analysis (2007-2011)
Covidien’s Revenue Share by Business Segments (2011)
1.4 European Hypertension Market
Covidien’s Revenues and Net Income Analysis (2007-2011)
Worldwide RDN Procedure Share by Geography (2012E and
Hypertension Prevalence
2020E)
Market Opportunity
Worldwide RDN Revenue Share by Geography (2012E and 2020E)
Global RDN Market Growth (2011-2015E)
2. Renal Denervation
2.1 Overview
RDN Device Comparison
RDN Application beyond Hypertension
2.2 Renal Denervation Market
Global Market
Europe
United States
Rest of World

7. View Report Details
3. Renal Denervation - Market Dynamics
Tables and Charts
3.1 Key Trends List of Tables
3.1.1 Medtronic’s HTN-3 Pivotal Study Classes of Essential Hypertension
3.1.2 Development of Novel Renal Denervation Devices Global Interventional Hypertension Market Model
3.1.3 Devising of Baroreceptor Stimulation Technology Patients Taking = 5 Hypertension Medications (2010)
3.1.4 Ongoing Clinical Trials U.S. Interventional Hypertension Unit Build (2010-2015E)
3.1.5 Addressing the Existing Limitations of the Current Developed Europe Interventional Hypertension Unit Build
Technologies Interventional Hypertension Treatment Products in Development
Global Renal Denervation Market (2011)
3.2 Growth Drivers European Renal Denervation Market (2011)
US Renal Denervation Market (2011)
3.2.1 Increasing Cases of Hypertension Rest of the World Renal Denervation Market (2011)
3.2.2 Increasing Expenditure on Healthcare Clinical Trials for Competitive Technologies
3.2.3 Rising Adult Population Worldwide Renal Denervation Programs
3.2.4 Increasing Global GNI (Gross National Income) Renal Denervation Technologies
Renal Denervation Competitive Technologies Under Development
3.3 Challenges Global RDN Procedures and Revenue Forecast (2012E-2020E)
Europe RDN Procedures and Revenue Forecast (2012E-2020E)
3.3.1 Limitations of Invasive Technology for Treatment The US RDN Procedures and Revenue Forecast (2012E-2020E)
3.3.2 Treatment-resistant Hypertension Japan RDN Procedures and Revenue Forecast (2014E-2020E)
Rest of the World RDN Procedures and Revenue Forecast
4. Renal Denervation - Competitive Landscape (2012E-2020E)
Competitive Overview
Renal Denervation Programs
Technology Comparison
5. Company Profiles
5.1 Medtronic
Business Overview
Financial Overview
Business Strategies
Expanding Market Share/Product Portfolio
Marketing and Distribution Tactics

8. View Report Details
5.2 St. Jude Medical
Business Overview
Financial Overview
Business Strategies
Innovative Device Fabrication
Portfolio Expansion through Acquisitions
5.3 Boston Scientific
Business Overview
Financial Overview
Business Strategies
Focus on Research & Development
Improving Financial Flexibility
5.4 Covidien
Business Overview
Financial Overview
Business Strategies
Emphasis on Innovation
Focus on Operational Excellence
6. RDN Market Outlook
Global Market
Europe
United States
Rest of World

9. View Report Details
Contact Us:
These are abridged and sanitized sample pages from the comprehensive report on the “Global Renal Denervation Market”. To
know more about this report or for any customized research requirement, please contact the following:
Koncept Analytics
CS-36, Second Floor, Ansal Plaza
Vaishali, Ghaziabad,
U.P. – 201010
Vikas Gupta T. +91-120-4130959
BD Manager C: +91-9811715635
vikas@konceptanalytics.com
www.konceptanalytics.com